公开(公告)号：US20140322179A1

公开(公告)日：2014-10-30

申请号：US14329510

申请日：2014-07-11

Applicant: Michel Revel ,  Judith Chebath ,  Michal Izrael ,  Rosalia Kaufman

Inventor： Michel Revel ,  Judith Chebath ,  Michal Izrael ,  Rosalia Kaufman

IPC: C12N5/079 ,  A61K35/30 ,  G01N33/50 ,  C12N5/0793

CPC classification number: C12N5/0622 ,  A61K35/30 ,  C12N5/0619 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/385 ,  C12N2501/41 ,  C12N2506/02 ,  C12N2533/52 ,  C12N2533/90 ,  G01N33/5058

Abstract: A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

Abstract translation: 提供了一种产生神经和神经胶质细胞的方法。 该方法包括在诱导所述人类干细胞分化为神经和神经胶质细胞的条件下培养人类干细胞，所述条件包括视黄酸和能够下调骨形态发生蛋白活性的试剂的存在。

公开(公告)号：US08394367B2

公开(公告)日：2013-03-12

申请号：US11579034

申请日：2005-04-28

Applicant: Michel Revel ,  Judith Chebath ,  Hagit Krug

Inventor： Michel Revel ,  Judith Chebath ,  Hagit Krug

IPC: A61K38/17 ,  A61K38/20 ,  A61K48/00

CPC classification number: A61K38/204

Abstract: The invention relates to the use of IL-6R/IL-6 chimera in chemotherapy induced neuropathy.

Abstract translation: 本发明涉及IL-6R / IL-6嵌合体在化疗诱发性神经病变中的应用。

公开(公告)号：US07374912B2

公开(公告)日：2008-05-20

申请号：US11688640

申请日：2007-03-20

Applicant: Michel Revel ,  Judith Chebath ,  Tsvee Lapidot ,  Orit Kollet

Inventor： Michel Revel ,  Judith Chebath ,  Tsvee Lapidot ,  Orit Kollet

IPC: C12N15/24 ,  C12N15/63 ,  C07H21/04

CPC classification number: C12N15/62 ,  A61K38/00 ,  C07K14/5412 ,  C07K14/7155 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/32 ,  C07K2319/71 ,  C07K2319/95

Abstract: Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.

Abstract translation: 提供由天然存在形式的可溶性IL-6受体和IL-6融合构建的嵌合蛋白，其可用于治疗癌症和肝脏疾病，增强骨髓移植和治疗其他IL-6相关病症。 。

公开(公告)号：US20060147436A1

公开(公告)日：2006-07-06

申请号：US11350094

申请日：2006-02-09

Applicant: Michel Revel ,  Carolina Abramovitch ,  Judith Chebath

Inventor： Michel Revel ,  Carolina Abramovitch ,  Judith Chebath

IPC: A61K48/00 ,  C12N15/87

CPC classification number: C12N9/1007 ,  A61K38/21 ,  C07K14/4702 ,  C07K14/555 ,  A61K2300/00

Abstract: Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.

公开(公告)号：US5621077A

公开(公告)日：1997-04-15

申请号：US329785

申请日：1994-10-27

Applicant: Daniela Novick ,  Louise Chen ,  Hartmut Engelmann ,  Michel Revel ,  Menachem Rubinstein ,  David Wallach

Inventor： Daniela Novick ,  Louise Chen ,  Hartmut Engelmann ,  Michel Revel ,  Menachem Rubinstein ,  David Wallach

IPC: G01N33/53 ,  A61K38/00 ,  A61K38/21 ,  A61K39/395 ,  A61P35/00 ,  C07K1/18 ,  C07K1/20 ,  C07K1/22 ,  C07K14/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/555 ,  C07K14/565 ,  C07K14/705 ,  C07K14/715 ,  C07K16/00 ,  C12N15/12 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  G01N33/577

CPC classification number: C07K14/715 ,  A61K38/215 ,  C07K14/7155 ,  Y10S530/834

Abstract: Human natural IFN-.beta.2/IL-6 receptor and its soluble extracellular fragment are provided in substantially purified form and are shown to stimulate and to enhance beneficial effects of IFN-.beta.2/IL-6, such as its antiproliferative activity. Polyclonal and monoclonal antibodies raised against the soluble fragment of the receptor are also provided.

Abstract translation: 以天然IFN-β2/ IL-6受体及其可溶性细胞外片段提供基本上纯化的形式，并显示刺激和增强IFN-β2/ IL-6的有益效果，如其抗增殖活性。 还提供针对受体的可溶性片段产生的多克隆和单克隆抗体。

公开(公告)号：US5510472A

公开(公告)日：1996-04-23

申请号：US883633

申请日：1992-05-15

Applicant: Michel Revel ,  Pierre Tiollais

Inventor： Michel Revel ,  Pierre Tiollais

IPC: A61K38/00 ,  A61K38/21 ,  C07K14/54 ,  C07K14/565 ,  C12N15/22 ,  C12N15/24

CPC classification number: A61K38/215 ,  C07K14/5412 ,  C07K14/565

Abstract: Human interferon-beta.sub.2.sbsb.A and interferon-beta.sub.2.sbsb.B are produced in purified form by recombinant DNA techniques. Two separate human genes have been identified which code for the production of IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B, respectively. The sequence of IFN-.beta..sub.2.sbsb.A cDNA is established. These genes and cDNA have been cloned into mammalian cells with an SV40 early promoter sequence and such genomic clones are capable of producing IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B. The antiviral activity of such recombinant IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B is demonstrated as well as other biological activity identifying them as human interferons.

Abstract translation: 通过重组DNA技术以纯化形式产生人干扰素-β2A和干扰素-β2B。 已经鉴定出分别编码IFN-β2A和IFN-β2B的两种分离的人类基因。 建立了IFN-β2AcDNA序列。 这些基因和cDNA已经用SV40早期启动子序列克隆到哺乳动物细胞中，并且这样的基因组克隆能够产生IFN-β2A和IFN-β2B。 证明了这种重组IFN-β2A和IFN-β2B的抗病毒活性以及将其识别为人类干扰素的其他生物学活性。

公开(公告)号：US5468608A

公开(公告)日：1995-11-21

申请号：US425935

申请日：1982-09-28

Applicant: Michel Revel ,  Pierre Tiollais

Inventor： Michel Revel ,  Pierre Tiollais

IPC: C12N15/09 ,  C07H21/02 ,  C07H21/04 ,  C07K14/54 ,  C07K14/565 ,  C12N15/00 ,  C12N15/22 ,  C12P19/34 ,  C12P21/00 ,  C12P21/02 ,  C12R1/19 ,  C12R1/91

CPC classification number: C07K14/5412 ,  C07K14/565

Abstract: The present invention relates to a process to isolate genetic material (DNA) containing the nucleotide sequence coding for interferon in human fibroblastic cells which comprises cultivating cells producing interferon when exposed to an inducer of interferon, exposing same to such inducer, extracting messenger RNA from said induced cells, purifying the interferon messenger RNA, transcribing the messenger RNA into DNA and cloning the DNA in a suitable vector. Preferred cells are human diploid foreskin cells. The invention further relates to a process for engineering a bacterial strain to produce interferon polypeptide which comprises introducing a cloned interferon DNA into a suitable vector-carrier. A preferred vector-carrier is E. coli. The invention also relates to the mRNA of human interferon in highly purified form, to the mRNA of human interferon in .beta.1 highly purified form, to the mRNA of human interferon in .beta.2 highly purified form, to the DNA coding for a polypeptide having interferon activity, insertable in a vector, such as plasmid pBR322, and also to human interferon .beta.1 in highly purified form, and human interferon .beta.2 in highly purified form.

公开(公告)号：US5047435A

公开(公告)日：1991-09-10

申请号：US328767

申请日：1989-03-27

Applicant: David Lavie ,  Daniel Meruelo ,  Gad Lavie ,  Michel Revel ,  Vincent Vande Velde ,  Dalia Rotman

Inventor： David Lavie ,  Daniel Meruelo ,  Gad Lavie ,  Michel Revel ,  Vincent Vande Velde ,  Dalia Rotman

IPC: A61K31/12 ,  A61K45/08

CPC classification number: A61K31/12

Abstract: Pharmaceutical formulations comprising aromatic polycyclic dione compounds useful for treating mammals suffering from diseases caused by retroviruses are disclosed herein. A method for treating mammals suffering from retrovirus infections is also disclosed.

Abstract translation: 本文公开了包含用于治疗患有由逆转录病毒引起的疾病的哺乳动物的芳香族多环二酮化合物的药物制剂。 还公开了治疗患有逆转录病毒感染的哺乳动物的方法。

公开(公告)号：US4622292A

公开(公告)日：1986-11-11

申请号：US525618

申请日：1983-08-22

Applicant: Michel Revel ,  David Wallach

Inventor： Michel Revel ,  David Wallach

IPC: G01N33/53 ,  C12Q1/00 ,  C12Q1/37 ,  C12Q1/70 ,  G01N33/569 ,  G01N33/68 ,  G01N33/545 ,  G01N33/60

CPC classification number: C12Q1/70 ,  G01N33/56983 ,  G01N33/6866 ,  Y10S435/84 ,  Y10S435/975 ,  Y10S436/804 ,  Y10S436/808 ,  Y10S436/828

Abstract: An assay and kit for the detection and quantitative determination of interferon. The assay is based on the exposure of certain cells to a solution containing the interferon which is to be determined, infecting the cells with a certain virus, incubating for a predetermined period of time, lysing the infected cultures and determining the virus protein. The measurement of the virus proteins can be effected by ELISA or radioimmunoassay.

Abstract translation: 用于检测和定量测定干扰素的测定和试剂盒。 该测定是基于某些细胞暴露于含有待测定的干扰素的溶液，用特定病毒感染细胞，孵育预定时间段，裂解感染的培养物并测定病毒蛋白质。 病毒蛋白质的测量可以通过ELISA或放射免疫测定来实现。

公开(公告)号：US09404087B2

公开(公告)日：2016-08-02

申请号：US13989805

申请日：2011-12-15

Applicant: Michel Revel ,  Judith Chebath ,  Guy Slutsky ,  Alon Levy ,  Michal Izrael ,  Arik Hasson ,  Kfir Molakandov ,  Rosalia Kaufman

Inventor： Michel Revel ,  Judith Chebath ,  Guy Slutsky ,  Alon Levy ,  Michal Izrael ,  Arik Hasson ,  Kfir Molakandov ,  Rosalia Kaufman

IPC: C12N5/00 ,  C12N5/071 ,  C12N5/02

CPC classification number: C12N5/0676 ,  C12N5/0677 ,  C12N2500/38 ,  C12N2500/44 ,  C12N2501/01 ,  C12N2501/119 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/335 ,  C12N2501/385 ,  C12N2501/415 ,  C12N2501/58 ,  C12N2501/60 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2533/54 ,  C12N2533/74

Abstract: A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof.

Abstract translation: 公开了从多能干细胞产生胰岛细胞的方法。 该方法包括：（a）在分化培养基中培养多能干细胞，以将多能干细胞分化成内胚层细胞; 和（b）在包含至少一种生长因子，cAMP诱导剂和视黄酸（RA）的培养基中培养所述内胚层细胞，所述至少一种生长因子选自FGF10，bFGF和FGF7，以产生 进一步分化细胞; 和（c）在包含选自烟酰胺，GLP-1和毒蜥外泌肽4的成熟因子的培养基中培养进一步分化的细胞，从而从多能干细胞产生胰岛细胞。 还公开了产生胰岛细胞的其它方法，包含其的分离的细胞群体及其用途。